Efficacy observation of apatinib combined with capecitabine in the treatment of advanced esophageal cancer

Q4 Medicine

肿瘤研究与临床 Pub Date : 2020-03-28 DOI:10.3760/CMA.J.CN115355-20190515-00202

H. Ye, Xiao-xiang Yin, Ying Zhao, L. Gu

{"title":"Efficacy observation of apatinib combined with capecitabine in the treatment of advanced esophageal cancer","authors":"H. Ye, Xiao-xiang Yin, Ying Zhao, L. Gu","doi":"10.3760/CMA.J.CN115355-20190515-00202","DOIUrl":null,"url":null,"abstract":"Objective \nTo observe the efficacy of apatinib combined with capecitabine in the treatment of advanced esophageal cancer. \n \n \nMethods \nA total of 101 patients with advanced esophageal cancer in Taixing People's Hospital of Jiangsu Province from June 2017 to February 2018 were enrolled, and all the patients were divided into the control group (50 cases) and the observation group (51 cases) according to the random number table. The control group was treated with capecitabine combined with radiotherapy, and the observation group was treated with apatinib on the basis of the control group. The therapeutic effects, adverse reactions and progression-free survival (PFS) time of the two groups were compared. \n \n \nResults \nThe overall response rate in the observation group was higher than that in the control group [90.2% (46/51) vs. 72.0% (36/50)], and the difference was statistically significant (χ2 = 5.473, P = 0.019). There were no significant differences in leukopenia, neutropenia, thrombocytopenia, anemia, proteinuria and hypertension between the two groups (all P > 0.05). The median PFS time in the observation group was 18.49 months (95% CI 15.35-25.03 months), and that in the control group was 13.33 months (95% CI 10.36-18.24 months), and the difference between the two groups was statistically significant (χ2 = 5.995, P < 0.01). \n \n \nConclusions \nThe therapeutic effect of apatinib combined with capecitabine in the treatment of advanced esophageal cancer is accurate. No obvious adverse reaction occurs, and the PFS time is prolonged. \n \n \nKey words: \nEsophageal neoplasms; Drug therapy, combination; Apatinib; Capecitabine","PeriodicalId":9505,"journal":{"name":"肿瘤研究与临床","volume":"32 1","pages":"170-173"},"PeriodicalIF":0.0000,"publicationDate":"2020-03-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"肿瘤研究与临床","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.3760/CMA.J.CN115355-20190515-00202","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"Medicine","Score":null,"Total":0}

引用次数: 0

Abstract

Objective To observe the efficacy of apatinib combined with capecitabine in the treatment of advanced esophageal cancer. Methods A total of 101 patients with advanced esophageal cancer in Taixing People's Hospital of Jiangsu Province from June 2017 to February 2018 were enrolled, and all the patients were divided into the control group (50 cases) and the observation group (51 cases) according to the random number table. The control group was treated with capecitabine combined with radiotherapy, and the observation group was treated with apatinib on the basis of the control group. The therapeutic effects, adverse reactions and progression-free survival (PFS) time of the two groups were compared. Results The overall response rate in the observation group was higher than that in the control group [90.2% (46/51) vs. 72.0% (36/50)], and the difference was statistically significant (χ2 = 5.473, P = 0.019). There were no significant differences in leukopenia, neutropenia, thrombocytopenia, anemia, proteinuria and hypertension between the two groups (all P > 0.05). The median PFS time in the observation group was 18.49 months (95% CI 15.35-25.03 months), and that in the control group was 13.33 months (95% CI 10.36-18.24 months), and the difference between the two groups was statistically significant (χ2 = 5.995, P < 0.01). Conclusions The therapeutic effect of apatinib combined with capecitabine in the treatment of advanced esophageal cancer is accurate. No obvious adverse reaction occurs, and the PFS time is prolonged. Key words: Esophageal neoplasms; Drug therapy, combination; Apatinib; Capecitabine

查看原文本刊更多论文

阿帕替尼联合卡培他滨治疗晚期食管癌的疗效观察

目的观察阿帕替尼联合卡培他滨治疗晚期食管癌的疗效。方法选取2017年6月~ 2018年2月在江苏省泰兴市人民医院住院治疗的晚期食管癌患者101例，按随机数字表法分为对照组(50例)和观察组(51例)。对照组给予卡培他滨联合放疗，观察组在对照组基础上给予阿帕替尼治疗。比较两组患者的治疗效果、不良反应及无进展生存期(PFS)。结果观察组总有效率高于对照组[90.2%(46/51)比72.0%(36/50)]，差异有统计学意义(χ2 = 5.473, P = 0.019)。两组患者白细胞减少、中性粒细胞减少、血小板减少、贫血、蛋白尿、高血压的发生率比较，差异均无统计学意义(P < 0.05)。观察组患者PFS中位时间为18.49个月(95% CI 15.35 ~ 25.03个月)，对照组患者PFS中位时间为13.33个月(95% CI 10.36 ~ 18.24个月)，两组比较差异有统计学意义(χ2 = 5.995, P < 0.01)。结论阿帕替尼联合卡培他滨治疗晚期食管癌疗效准确。无明显不良反应发生，PFS时间延长。关键词:食管肿瘤;药物治疗、联合用药;Apatinib;卡培他滨

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

肿瘤研究与临床 Medicine-Oncology

CiteScore

0.10

自引率

0.00%

发文量

7737

期刊介绍： "Cancer Research and Clinic" is a series of magazines of the Chinese Medical Association under the supervision of the National Health Commission and sponsored by the Chinese Medical Association. It mainly reflects scientific research results and academic trends in the field of malignant tumors. The main columns include monographs, guidelines and consensus, standards and norms, treatises, short treatises, survey reports, reviews, clinical pathology (case) discussions, case reports, etc. The readers are middle- and senior-level medical staff engaged in basic research and clinical work on malignant tumors.